• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Help for light-hair laser reduction


Pipeline topical silver photo-particle solution aids laser in removing tough-to-treat white, gray, blonde, light red and light brown hair.

laser hair removal

Pipeline topical silver photo-particle solution aids laser in removing tough-to-treat white, gray, blonde, light red and light brown hair. (Микола Ковальчинськи - stock.adobe.com)

When combined with the 810 nm diode laser for hair removal, SNA-001 (Sienna Biopharmaceuticals), a pipeline topical silver photo-particle solution and light absorber, helped to remove tough-to-treat white, gray, blonde, light red and light brown hair in men and women, according to a Sienna Biopharmaceuticals press release dated Feb. 8, 2019.

Sienna describes the technology as using silver particles applied to the skin to harness light energy from medical lasers to thermally target hair follicles inside pilosebaceous units. Lasers activate the silver particles to thermally target hair follicles without damaging surrounding tissue.

Sienna released results from a pivotal trial of SNA-001 involving 65 patients having hair removal with the 810 nm diode laser. After six treatments, hair decreased an average 17.5% with topical SNA-001 pretreatment and laser compared to an average 1.1% in those receiving vehicle and laser. Adding the ready-to-use suspension of silver particles before laser treatment resulted in up to a 32% reduction of light hair compared to baseline, making it statistically superior to vehicle and laser, according to the company.

Researchers also studied SNA-001 in hair removal patients treated with the 1064 Nd:YAG and 755 nm Alexandrite laser. In both cases, study authors reported a significant reduction in light hair from baseline but the difference between patients who received SNA-001 and those who did not in conjunction with these laser devices wasn’t as significant as with the 810 nm diode.

The company also announced that a third and final pivotal trial of SNA-001 in acne showed the topical solution was non-inferior to laser therapy. But previous studies on SNA-001 in acne were less successful. Last year, Sienna Biopharmaceuticals announced that two pivotal acne trials with SNA-001 in conjunction with 1064 nm and 810 nm lasers did not show statistical significance on the primary and secondary endpoints, according to a July 30, 2018, article on StreetInsider.com

The most recent results pave a possible path to SNA-001’s regulatory clearance in light-pigmented hair removal and acne, according to the company.

SNA-001 is part of Sienna’s proprietary Topical Photoparticle Therapy platform. The company’s President and Chief Executive Officer Frederick C. Beddingfield III, M.D., Ph.D., described some of Sienna’s other projects in a March 14, 2019, press release: “Our drive to bring unconventional scientific innovations to patients whose lives remain burdened by their disease without compromising safety has unlocked a pipeline of selective kinase inhibitors that target select pathways in specific tissues to treat a variety of chronic inflammatory and immunologic conditions with minimal to no systemic exposure. We are poised to begin Phase 3 enrollment for SNA-120 (pegcantratinib) later this year as a potential first-in-class, non-steroidal treatment for psoriasis and the associated pruritus. Additionally, we continue to see potential in SNA-125, our tissue-targeted JAK3/TrkA dual kinase inhibitor, for other inflammatory disorders of the skin, as well the gastrointestinal tract, the eye and the lung. Indeed, with additional funding through a business-development transaction or other means, we would plan to move SNA-125 forward with a Phase 2 trial in atopic dermatitis, as well as with a proof-of-concept study in ulcerative colitis, where the need for gut-restricted drugs with low systemic exposure is high.”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.